Investors are running into Viking Therapeutics (NASDAQ: VKTX) this week after an incident of drug-induced liver injury pushed ...

Viking Therapeutics (NasdaqCM:VKTX) saw its stock rise by 11% over the last week, coinciding with significant developments in its clinical trials. The company's completion of subject enrollment for ...

Discover why VKTX's deep selloff offers a compelling opportunity with improved safety margins, promising GLP-1 candidates, ...

Shares of Viking Therapeutics have sold off sharply as the market awaits updates on its drug candidates. The company is ...

H.C. Wainwright says the bar is set for oral GLP-1s following this morning’s type 2 diabetes data from Eli Lilly (LLY). The firm continues to expect Viking Therapeutics (VKTX) to “differentiate” with ...

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...

Viking Therapeutics (NASDAQ: VKTX) is a healthcare company that possesses a lot of growth potential. And last year, its ...

Discover how Viking Therapeutics, Inc.'s VK2735 and VK2809 target obesity and NASH markets. Click for my updated look at VKTX ...

Viking Therapeutics enjoyed a nice share rally on the news that rival Pfizer is discontinuing obesity candidate danuglipron.

Shares of Viking Therapeutics (VKTX) are moving lower in pre-market trading after Eli Lilly (LLY) announced topline Phase 3 results from ...

Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid ...

Phase 3 data for orforglipron in type 2 diabetes suggest a “highly competitive profile” for the drug. The firm views the data as its base case scenario, whereby Structure Therapeutics (GPCR) shares ...